Moreover, Xiao et al. elucidated that dysregulated expression in RNF7 affects proliferation and tumorigenesis, with this trend occurring within prostate cancer by inactivating ERK 1/2 pathway, suggesting that RNF7 can be used as tumor markers for PC treatment [15]. The gene discussed is RNF7; the disease is pachyonychia congenita.